PIOGLITAZONE ADJUNCTIVE THERAPY FOR DEPRESSIVE EPISODE OF BIPOLAR DISORDER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Depression and AnxietyVolume 32, Issue 3 p. 167-173 Research Article PIOGLITAZONE ADJUNCTIVE THERAPY FOR DEPRESSIVE EPISODE OF BIPOLAR DISORDER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL Atefeh Zeinoddini M.D., Atefeh Zeinoddini M.D. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IranSearch for more papers by this authorMaryam Sorayani M.D., Maryam Sorayani M.D. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IranSearch for more papers by this authorElmira Hassanzadeh M.D., Elmira Hassanzadeh M.D. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IranSearch for more papers by this authorMohammad Arbabi M.D., Mohammad Arbabi M.D. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IranSearch for more papers by this authorMehdi Farokhnia M.D., Mehdi Farokhnia M.D. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IranSearch for more papers by this authorSamrand Salimi M.D., Samrand Salimi M.D. Baharloo Hospital, Tehran University of Medical Sciences, Tehran, IranSearch for more papers by this authorAli Ghaleiha M.D., Ali Ghaleiha M.D. Research Center for Behavioral Disorders and Substance Abuse, Hamadan University of Medical Sciences, Hamadan, IranSearch for more papers by this authorShahin Akhondzadeh Ph.D., Corresponding Author Shahin Akhondzadeh Ph.D. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IranCorrespondence to: Prof. Shahin Akhondzadeh, Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 13337, Iran. E-mail: [email protected]Search for more papers by this author Atefeh Zeinoddini M.D., Atefeh Zeinoddini M.D. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IranSearch for more papers by this authorMaryam Sorayani M.D., Maryam Sorayani M.D. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IranSearch for more papers by this authorElmira Hassanzadeh M.D., Elmira Hassanzadeh M.D. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IranSearch for more papers by this authorMohammad Arbabi M.D., Mohammad Arbabi M.D. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IranSearch for more papers by this authorMehdi Farokhnia M.D., Mehdi Farokhnia M.D. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IranSearch for more papers by this authorSamrand Salimi M.D., Samrand Salimi M.D. Baharloo Hospital, Tehran University of Medical Sciences, Tehran, IranSearch for more papers by this authorAli Ghaleiha M.D., Ali Ghaleiha M.D. Research Center for Behavioral Disorders and Substance Abuse, Hamadan University of Medical Sciences, Hamadan, IranSearch for more papers by this authorShahin Akhondzadeh Ph.D., Corresponding Author Shahin Akhondzadeh Ph.D. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IranCorrespondence to: Prof. Shahin Akhondzadeh, Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 13337, Iran. E-mail: [email protected]Search for more papers by this author First published: 23 January 2015 https://doi.org/10.1002/da.22340Citations: 81 Contract grant sponsor: Tehran University of Medical Sciences; Contract grant number: 16043. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract Background The antidepressive effect of pioglitazone has been noted in patients with major depressive disorder in absence of metabolic syndrome. This study was conducted to evaluate the safety and efficacy of pioglitazone in patients with bipolar depression without concomitant metabolic syndrome or diabetes. Method Forty-eight outpatients with the diagnosis of bipolar I disorder and a major depressive episode participated in a parallel, randomized, double-blind, placebo-controlled trial, and 44 patients underwent 6-week treatment with either pioglitazone (30 mg/day) or placebo as an adjunctive treatment to lithium. Therapeutic serum lithium levels of 0.6–0.8 mEq/L were required for two or more consecutive weeks immediately before starting pioglitazone and during the 6-week study. Patients were evaluated using Hamilton Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS) at baseline and weeks 1, 2, 4, and 6. The primary outcome was to evaluate the efficacy of pioglitazone in improving the depressive symptoms. Result General linear model repeated measures showed significant effect for time × treatment interaction on the HDRS scores [F(2.78, 116.65) = 4.77, P = .005]. Significantly greater reduction was observed in HDRS scores in the pioglitazone group than the placebo group from baseline HDRS score at weeks 2, 4, and 6, P = .003, .006, and .006, respectively. No serious adverse event was observed. Conclusion This study showed that pioglitazone could be a tolerable and effective adjunctive therapy for improving depressive symptoms in bipolar disorder without type 2 diabetes or metabolic syndrome. Citing Literature Volume32, Issue3March 2015Pages 167-173 RelatedInformation